This is the SVF-2

The SVF-2 presents a major step forward for cellular medicine. In as little as 60 minutes, a small sample of tissue is used to create a cellular implant for targeted therapy.

Introducing the SVF-2

In a major development a single-use device and therapy could mean a major development in the treatment of pain and function associated with knee osteoarthritis. The SVF-2 uniquely harvests, isolates, and reimplants stromal progenitor cells to help control pain, reduce inflammation and repair inflamed tissue in the knee. FDA-approved clinical trials for this no-joint-surgery, minimally invasive option have shown no serious adverse events and significant improvements in pain, stiffness and function.

Musculoskeletal Therapies

Regain mobility and reduce pain with cellular therapies designed to reverse osteoarthritis; damage to tendons, ligaments, and discs; and simple & complex bone fractures.

Explore the Benefits

Coming Soon

Further clinical trials are already or will soon be underway to prove the SVF-2’s effectiveness in the treatment of osteoarthritis and rheumatoid arthritis throughout the body.

Pending Approval

The SVF-2 has been proven effective in the treatment of osteoarthritis in the knee and has been submitted to the FDA for approval.

Dermal Therapies

Repair the skin with cellular therapies designed to repair and reconstruct dermal tissue damaged by wounds, burns, scars, or radiation; peripheral vascular disease and diabetic foot ulcers. May also be effective in place of aesthetic surgeries, such as hair regeneration and skin rejuvenation.

Explore the Benefits

Coming Soon

Clinical trials of the SVF-2ʼs effectiveness in treating peripheral vascular disease in small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon.

Organ Therapies

Regenerate organ systems with cellular therapies developed to combat chronic obstructive pulmonary disease (COPD), erectile dysfunction, and kidney fibrosis.

Explore the Benefits

Coming Soon

Trials in erectile dysfunction, CPD, and kidney fibrosis are already underway.

Pipeline Overview

Pre-Clinical

Feasibility Safety/Efficacy

Pivotal Safety/Efficacy

FDA Market Approval

Osteoarthritis

The osteoarthritis trial is a multi-site pivotal clinical trial that is double-blinded, randomized, placebo-controlled, dose-escalated, and statistically powered. The trial has IDE approval by the FDA.

Diabetic Ulcers/Wounds’

Clinical trials for diabetic ulcers and wounds are safety and feasibility studies.

Erectile Dysfunction

The ED is a safety/feasibility clinical trial to assess use of SVF for treatment of ED. The trial has IDE approval by the FDA.

COPD

The COPD trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of COPD.

RA/OA Hands/Fingers

This trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of rheumatoid arthritis and osteoarthritis of the hands/fingers.